| Variant | Gene | Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
0.800 | GeneticVariation | GWASDB | Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women. | 21507922 | 2011 | |||||||
|
|
|
0.800 | GeneticVariation | GWASCAT | Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women. | 21507922 | 2011 | |||||||
|
|
|
T | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
A | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
CA | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
C | 0.700 | CausalMutation | CLINVAR | |||||||||
|
|
|
A | 0.700 | GeneticVariation | CLINVAR | |||||||||
|
|
|
0.070 | GeneticVariation | BEFREE | Calreticulin (CALR) gene mutations are currently recommended as biomarkers in diagnosis of patients with myeloproliferative neoplasms (MPN) with Jak2 V617F negative phenotype. | 31248375 | 2019 | |||||||
|
|
|
0.070 | GeneticVariation | BEFREE | Calreticulin (CALR) gene mutations are currently recommended as biomarkers in diagnosis of patients with myeloproliferative neoplasms (MPN) with Jak2 V617F negative phenotype. | 31248375 | 2019 | |||||||
|
|
|
0.070 | GeneticVariation | BEFREE | Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. | 26617890 | 2015 | |||||||
|
|
|
0.070 | GeneticVariation | BEFREE | JAK2 V617F mutation is a molecular marker for myeloproliferative neoplasms (MPNs). | 25015634 | 2014 | |||||||
|
|
|
0.070 | GeneticVariation | BEFREE | Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2 (V617F) mutations. | 24475114 | 2014 | |||||||
|
|
|
0.070 | GeneticVariation | BEFREE | The JAK2-V617F mutation is prevalent in almost all patients with MPNs and has become a valuable biomarker for diagnosis of MPNs. | 24362471 | 2014 | |||||||
|
|
|
0.070 | GeneticVariation | BEFREE | Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2 (V617F) mutations. | 24475114 | 2014 | |||||||
|
|
|
0.070 | GeneticVariation | BEFREE | JAK2 V617F mutation is a molecular marker for myeloproliferative neoplasms (MPNs). | 25015634 | 2014 |